The GLP-1 agonists market report provides insights around existing treatment practices in patients with Glucagon-like Peptide-1 (GLP-1) Agonists, approved (if any) and emerging Glucagon-like Peptide-1 (GLP-1) Agonists, market share of individual therapies, patient pool eligible for treatment with Glucagon-like Peptide-1 (GLP-1) Agonists, along with current and forecasted 7MM Glucagon-like Peptide-1 (GLP-1) Agonists market size from 2020-2034 by therapies and by indication
SGLT2 inhibitors and GLP-1 agonists should be used as early as possible in the diabetes course to provide the most cardiac benefit, Joanna Khatib, MBBS, an endocrinology fellow at Tulane University School of Medicine, told Healio
Patients are also encouraged to adopt other healthy habits, such as regular exercise, into their daily routine
GLP-1 Compliance during Shortages: GLP-1 medications have been in high demand, leading to gaps in compliance
Upon arrival, immediate refrigeration at 20C is recommended